Premalignant Lesions of the Gastrointestinal Tract

1. ESOPHAGUS

A. Barrett's Esophagus (BE)

• Chronic gastroesophageal reflux damages squamous epithelium
• A process of "cellular reprogramming" driven by BARX1 and other developmental factors causes squamous-to-columnar metaplasia incorporating intestinal mucosa (goblet cells)
• Metaplastic Barrett cells first acquire a p53 mutation, then proceed via two molecular routes:
  • Traditional pathway: stepwise accumulation in CDKN2A/p16, KRAS, and finally p53 loss
  • Genome-doubled pathway (more rapid): p53-mutant cells undergo whole-genome doubling followed by genomic instability and oncogene amplification - thought to explain rapid cancer progression missed on surveillance

• Dysplasia = histological expression of the genetic changes; categorized as low-grade dysplasia (LGD) or high-grade dysplasia (HGD)
• Endoscopically, dysplasia may appear as ulcerations, nodules, mucosal irregularities - but can be invisible to the naked eye
• Seattle biopsy protocol: four-quadrant biopsies every 1-2 cm of columnar-lined esophagus
• Advanced imaging: Narrow Band Imaging (NBI), chromoendoscopy, confocal laser endomicroscopy, volumetric laser endomicroscopy (VLE)

• Screening EGD indicated for patients with ≥10 years of GERD, even if symptoms are mild
• Periodic surveillance EGD with biopsies for all confirmed BE patients
• LGD: both periodic surveillance and endoscopic eradication therapy (EET) are acceptable
• HGD or intramucosal cancer: EET is the procedure of choice; esophagectomy only in unusual circumstances
• EET modalities: Radiofrequency ablation (RFA) - most common; Cryotherapy; Endoscopic mucosal resection (EMR); Endoscopic submucosal dissection (ESD)

B. Esophageal Squamous Dysplasia

• The precursor lesion of esophageal squamous cell carcinoma (ESCC), the most common esophageal malignancy worldwide
• Often requires specialized imaging for detection: chromoendoscopy with Lugol's iodine solution
• Population-based screening in high-incidence regions (China, Iran, Central Asia) has been shown to reduce ESCC occurrence
• Treatment when detected: EMR, ESD, or RFA

2. STOMACH

A. Chronic Atrophic Gastritis + Intestinal Metaplasia (Correa Cascade)

Normal gastric mucosa → Chronic superficial gastritis (H. pylori) → Chronic atrophic gastritis → Intestinal metaplasia → Dysplasia → Carcinoma

• Chronic atrophic gastritis: loss of normal gastric glands, associated with H. pylori infection or autoimmune destruction (pernicious anemia). On endoscopy, disappearance of rugal folds, enhanced mucosal vasculature
• Intestinal metaplasia (IM): replacement of gastric mucosa with intestinal mucosa (goblet cells). Appears as gray-white patches on white-light endoscopy. A classic premalignant lesion. May represent reactivation of developmental intestinal programs
• Gastric dysplasia: the direct precursor to invasive carcinoma; classified as LGD or HGD

• H. pylori eradication is indicated for patients with preneoplastic lesions (atrophic gastritis or intestinal metaplasia)
• Evidence on regression of IM after H. pylori eradication is mixed; no significant difference in IM regression between treated and untreated H. pylori-negative IM patients at 2 years in RCT data
• A recent systematic review (Dinis-Ribeiro et al., Gut 2024, PMID 39122364) addresses worldwide guidelines for managing gastric intestinal metaplasia

• Patients with atrophic gastritis/IM: EGD surveillance is recommended
• Testing and treatment for H. pylori is mandatory in all patients found to have premalignant gastric lesions

B. Gastric Adenomas (Gastric Polyps)

• True gastric adenomas are premalignant - risk correlates with size and degree of villous architecture
• Patients with Familial Adenomatous Polyposis (FAP) also develop gastric polyps (including fundic gland polyps and duodenal/gastric adenomas)
• Gastric carcinoma may develop remote from a hyperplastic polyp in areas of associated chronic inflammation
• Hyperplastic polyps per se carry low malignant potential but are a marker of the inflammatory milieu

3. COLORECTUM

A. Adenomatous Polyps (Conventional Adenomas)

• ~25% of Americans have adenomatous polyps by age 50; up to 50% of 70-year-olds
• <5% of adenomatous polyps are expected to progress to adenocarcinoma
• Development from polyp to invasive cancer typically takes 10-15 years

• Size: Adenomas <1 cm - cancer extremely rare; adenomas >4 cm - up to ~40% contain invasive cancer
• Architecture: Villous adenomas develop cancer 3× more often than tubular adenomas
• High-grade dysplasia: Second major risk factor

FIG. 13.33 - Colonic adenomas: (A) pedunculated adenoma (endoscopic view), (B) adenoma with velvety surface, (C) low-magnification histology of a pedunculated tubular adenoma. - Robbins & Kumar Basic Pathology

FIG. 13.34 - (A) Tubular adenoma with smooth surface and rounded glands; (B) Villous adenoma with long slender projections; (C) Dysplastic epithelium with hyperchromatic pseudostratified nuclei; (D) Sessile serrated adenoma with goblet cells and crypt involvement. - Robbins & Kumar Basic Pathology

1. Chromosomal instability (CIN) pathway - most common; early APC loss, then KRAS/BRAF, then p53 loss
2. Mismatch repair (MMR) deficiency/microsatellite instability (MSI-high) - underlying mechanism of Lynch syndrome; tumors sensitive to immune checkpoint inhibitors
3. CpG island methylation (CIMP) - often right-sided, associated with MLH1 methylation; can be MSI-high or MSS

B. Hyperplastic Polyps

• Common epithelial proliferations in the sixth-seventh decades
• Pathogenesis: decreased epithelial cell turnover → "pileup" of goblet cells
• The traditional view was that they are benign with no malignant potential
• However, sessile serrated adenomas (SSAs) - which overlap histologically with hyperplastic polyps - DO carry malignant potential and must be distinguished from simple hyperplastic polyps
• Key distinguishing feature: in SSA, serrated architecture extends through the full crypt length to the base, with crypt dilation and lateral growth; in hyperplastic polyp, serration is confined to the surface

C. Hamartomatous Polyposis Syndromes

D. Colitis-Associated Neoplasia (IBD-associated dysplasia)

• Duration of disease: Risk begins to rise 8-10 years after diagnosis
• Extent of involvement: Pancolitis > left-sided or proctitis
• Severity and frequency of active inflammation (neutrophilic)
• Primary sclerosing cholangitis (PSC): Markedly greater risk; surveillance initiated at time of PSC diagnosis, not 8 years later

• Colonoscopic surveillance recommended starting 8 years after IBD diagnosis
• Extensive mucosal biopsies required; dysplasia frequently occurs in flat mucosa that appears grossly normal
• Advanced endoscopic imaging (NBI, chromoendoscopy) helps target dysplastic areas

4. HEREDITARY SYNDROMES - A FOCUSED SUMMARY

5. SUMMARY TABLE: PREMALIGNANT LESIONS BY GI SITE

Key Takeaways

1. Dysplasia is the common histological endpoint of all GI premalignant lesions - it is the morphological manifestation of accumulated genetic/epigenetic mutations
2. H. pylori drives the gastric premalignant cascade and eradication is mandatory in all patients with preneoplastic gastric lesions
3. Polyp size and villous architecture are the two most important determinants of malignant risk in colorectal adenomas; lesions >4 cm harbor cancer in ~40% of cases
4. Surveillance endoscopy with targeted biopsy is the cornerstone of management across all GI premalignant conditions
5. Endoscopic eradication (RFA, EMR, ESD) has largely replaced surgery for esophageal dysplasia (Barrett's HGD) and is increasingly applied for gastric lesions
6. Hereditary syndromes (FAP, Lynch, PJS) require genetic testing, family screening, and often prophylactic surgery